Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis

Journal of Immunological Methods

Volumn 395, Issue 1-2, 2013, Pages 14-20

  Choi, Bryan D ^a   Gedeon, Patrick C ^a,b   Kuan, Chien Tsun ^a   Sanchez Perez, Luis ^a   Archer, Gary E ^a   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duke University   (United States)

Author keywords

Bispecific antibodies; Complementarity determining regions; Epidermal growth factor receptor; Site directed mutagenesis

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; REAGENT; TUMOR ANTIGEN;

ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CD3+ T LYMPHOCYTE; CELL INCLUSION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ESCHERICHIA COLI; EVALUATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE;

BISPECIFIC ANTIBODIES; COMPLEMENTARITY DETERMINING REGIONS; EPIDERMAL GROWTH FACTOR RECEPTOR; SITE-DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD3; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; FLOW CYTOMETRY; GLIOMA; HUMANS; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ALIGNMENT; SINGLE-CHAIN ANTIBODIES; SURFACE PLASMON RESONANCE;

EID: 84881559338     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.06.003     Document Type: Article

References (25)

1. Arakawa F., Kuroki M., Kuwahara M., Senba T., Ozaki H., Matsuoka Y., Misumi Y., Kanda H., Watanabe T. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J. Biochem. 1996, 120:657.
2. Baeuerle P.A., Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69:4941.
3. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmuller G., Reinhardt C., Baeuerle P.A., Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974.
4. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10:345.
5. Casson L.P., Manser T. Evaluation of loss and change of specificity resulting from random mutagenesis of an antibody VH region. J. Immunol. 1995, 155:5647.
6. Choi B.D., Cai M., Bigner D.D., Mehta A.I., Kuan C.T., Sampson J.H. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert. Opin. Biol. Ther. 2011, 11:843.
7. Choi B.D., Kuan C.T., Cai M., Archer G.E., Mitchell D.A., Gedeon P.C., Sanchez-Perez L., Pastan I., Bigner D.D., Sampson J.H. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:270.
8. Choi B.D., Pastan I., Bigner D.D., Sampson J.H. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. OncoImmunology 2013, 2:e23639.
9. Dreier T., Baeuerle P.A., Fichtner I., Grun M., Schlereth B., Lorenczewski G., Kufer P., Lutterbuse R., Riethmuller G., Gjorstrup P., Bargou R.C. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J. Immunol. 2003, 170:4397.
10. Gruber M., Schodin B.A., Wilson E.R., Kranz D.M. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 1994, 152:5368.
11. Hammond S.A., Lutterbuese R., Roff S., Lutterbuese P., Schlereth B., Bruckheimer E., Kinch M.S., Coats S., Baeuerle P.A., Kufer P., Kiener P.A. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 2007, 67:3927.
12. Heckman K.L., Pease L.R. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat. Protoc. 2007, 2:924.
13. Kipriyanov S.M., Moldenhauer G., Braunagel M., Reusch U., Cochlovius B., Le Gall F., Kouprianova O.A., Von der Lieth C.W., Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 2003, 330:99.
14. Kranz D.M., Voss E.W. Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:5807.
15. Kuan C.T., Reist C.J., Foulon C.F., Lorimer I.A., Archer G., Pegram C.N., Pastan I., Zalutsky M.R., Bigner D.D. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin. Cancer Res. 1999, 5:1539.
16. Landry R.C., Klimowicz A.C., Lavictoire S.J., Borisova S., Kottachchi D.T., Lorimer I.A., Evans S.V. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor EGFRvIII. J. Mol. Biol. 2001, 308:883.
17. List T., Neri D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. mAbs 2012, 4.
18. Mallender W.D., Voss E.W. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J. Biol. Chem. 1994, 269:199.
19. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:7727.
20. Nuttall S.D., Irving R.A., Hudson P.J. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr. Pharm. Biotechnol. 2000, 1:253.
21. O'Gorman M.R., Thomas J. Isotype controls-time to let go?. Cytometry 1999, 38:78.
22. Schlereth B., Fichtner I., Lorenczewski G., Kleindienst P., Brischwein K., da Silva A., Kufer P., Lutterbuese R., Junghahn I., Kasimir-Bauer S., Wimberger P., Kimmig R., Baeuerle P.A. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 2005, 65:2882.
23. Schlereth B., Kleindienst P., Fichtner I., Lorenczewski G., Brischwein K., Lippold S., da Silva A., Locher M., Kischel R., Lutterbuse R., Kufer P., Baeuerle P.A. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol. Immunother. 2006, 55:785.
24. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 2001, 248:47.
25. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22:1393.